These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26022051)

  • 41. Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide.
    Sun Y; Kim SH; Zhou DC; Ding W; Paietta E; Guidez F; Zelent A; Ramesh KH; Cannizzaro L; Warrell RP; Gallagher RE
    Leukemia; 2004 Jul; 18(7):1258-69. PubMed ID: 15116119
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
    Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells.
    Herst PM; Hesketh EL; Ritchie DS; Berridge MV
    Leuk Res; 2008 Feb; 32(2):327-33. PubMed ID: 17580091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation.
    Dembitz V; Lalic H; Ostojic A; Vrhovac R; Banfic H; Visnjic D
    Int J Hematol; 2015 Jul; 102(1):12-24. PubMed ID: 25758096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
    Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [In vitro study on arsenic trioxide-induced apoptosis of retinoic acid resistant acute promyelocytic leukemia cell line(MR-2)].
    Cai X; Jia P; Shi X
    Zhonghua Xue Ye Xue Za Zhi; 1998 Jul; 19(7):339-41. PubMed ID: 11189513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of efficacy and adverse effects between arsenic trioxide and all-trans retinoic acid in patients with acute promyelocytic leukemia].
    Jiao L; Wang SJ; Zhuang JL; Zhao YQ; Zhou DB; Xu Y; Han B; Zhang W; Duan MH; Zou N; Zhu TN; Shen T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):555-8. PubMed ID: 19968069
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
    Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
    Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ATO Increases ROS Production and Apoptosis of Cells by Enhancing Calpain-Mediated Degradation of the Cancer Survival Protein TG2.
    Jambrovics K; Póliska S; Scholtz B; Uray IP; Balajthy Z
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The impact of arsenic trioxide or all-trans retinoic acid treatment on coagulopathy in acute promyelocytic leukemia].
    Zhang X; Zhou H; Song S; Qiao Z; Yang L; Hu Y
    Zhonghua Nei Ke Za Zhi; 2001 Dec; 40(12):829-33. PubMed ID: 16206674
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
    J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
    Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Arsenic trioxide augments all-trans retinoic acid-induced differentiation of HL-60 cells.
    Sumi D; Suzukawa K; Himeno S
    Life Sci; 2016 Mar; 149():42-50. PubMed ID: 26892147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
    Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
    J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Potentiation of arsenic trioxide-induced apoptosis by retinoic acid in retinoic acid sensitive and resistant HL-60 myeloid leukemia cells].
    Huang X
    Chin Med J (Engl); 2000 Jun; 113(6):498-501. PubMed ID: 11775865
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
    Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
    Xu L; Zeng Z; Zhang W; Ren G; Ling X; Huang F; Xie P; Su Y; Zhang XK; Zhou H
    Oncotarget; 2017 Feb; 8(7):12311-12322. PubMed ID: 28129653
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.
    Raffoux E; Rousselot P; Poupon J; Daniel MT; Cassinat B; Delarue R; Taksin AL; Réa D; Buzyn A; Tibi A; Lebbé G; Cimerman P; Chomienne C; Fermand JP; de Thé H; Degos L; Hermine O; Dombret H
    J Clin Oncol; 2003 Jun; 21(12):2326-34. PubMed ID: 12805334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
    Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.